💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Valsartan

CHEMBL1069 Phase 4 معتمد Small molecule
Half-Life
6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
435.5 g/mol
LogP
4.4
Phase
4

Receptor-level interruption of the renin-angiotensin system distinguishes valsartan from the ACE inhibitors: it blocks the angiotensin II type 1 receptor rather than the enzyme producing the hormone. Angiotensin II can therefore still be formed, but cannot constrict vascular smooth muscle, so vessels relax and blood pressure falls. Approved uses are hypertension, heart failure and improvement of survival after myocardial infarction. The class carries an absolute contraindication in pregnancy, since interference with the fetal renin-angiotensin system causes injury to the developing kidney. Its elimination half-life is about six hours. The compound belongs to the cardiovascular-system group, with formula C24H29N5O3 and a mass near 435.5 g/mol.

This angiotensin receptor blocker (ARB) is used to treat high blood pressure, heart failure, and to improve survival after a heart attack. It works by blocking the action of angiotensin II, a hormone that constricts blood vessels, allowing them to relax and lower blood pressure. Like all ARBs, it should not be taken during pregnancy.

الوزن الجزيئي

435,5190 g/mol

LogP

4,40

TPSA

112,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Cardiovascular Disease Obstetrics & Gynecology Hypertension Heart Failure

تصنيفات الأدوية

C — C - Cardiovascular System

آلية العمل

Angiotensin II type 1 receptor blocker.

Pharmacokinetics (PK)

Half-Life 6 hours

Pharmacodynamics (PD)

الآلية

Angiotensin II type 1 receptor blocker.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C

                

                

                
                

                    
InChI

                    
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H29N5O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
الروابط القابلة للدوران

                        
10

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
32

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            AGTR1 (Angiotensin II Type 1 Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Valsartan + Digoxin
                            
                        

                        
                        
Valsartan may slightly increase digoxin plasma levels by reducing its renal clearance; the interaction is generally modest.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
This angiotensin receptor blocker (ARB) is used to treat high blood pressure, heart failure, and to improve survival after a heart attack. It works by blocking the action of angiotensin II, a hormone that constricts blood vessels, allowing them to relax and lower blood pressure. Like all ARBs, it should not be taken during pregnancy.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Angiotensin II type 1 receptor blocker.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Valsartan: Half-life: 6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Valsartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1069.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60846.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.